Imperial spinout Emcision limited acquired by Boston Scientific

8 Mar 2018

Imperial Innovations, the technology commercialisation partner for Imperial College London, is pleased to announce that its portfolio company Emcision Limited has been acquired by Boston Scientific (NYSE: BSX). The financial terms of the transaction were not disclosed.

Emcision Limited, a spinout of Imperial College London, was founded in 1999 by Professor Nagy Habib, Professor of Hepatobiliary Surgery in the Department of Surgery and Cancer at Imperial College London.

The company developed the Habib™ EndoHPB probe, a novel endoscopic bipolar radiofrequency device, which coagulates tissue in the gastrointestinal tract. The Habib EndoHPB probe is used by physicians in the treatment and palliative care of patients living with pancreaticobiliary cancers. Pancreaticobiliary cancers account for nearly a million deaths annually worldwide and have limited treatment options. The EMcision products have helped thousands of patients worldwide with these difficult to treat cancers for whom surgery is not an option.

Read Boston Scientific's release